Clinical Trial Detail

NCT ID NCT04388852
Title DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

prostate neuroendocrine neoplasm

prostate carcinoma

transitional cell carcinoma

prostate small cell carcinoma

clear cell renal cell carcinoma

Therapies

DS-3201b + Ipilimumab

Age Groups: senior adult

Additional content available in CKB BOOST